Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 10 includes Advanced Micro Devices, Novo Nordisk ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst was upbeat.

The FDA announced in late December that it had approved Eli Lilly's Zepbound (tirzepatide ... Despite device sales and masks sales that both increased 12% in the U.S., Canada and Latin America in the ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

In this article, we are going to take a look at where Eli Lilly ... Mounjaro and Zepbound weekly scripts are finally, finally doing good. And they have been not good. . . .” “Lilly versus ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.